K. Anderes

发表

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

D. V. Von Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012, Molecular Cancer Therapeutics.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

R. Hannan, M. Bywater, E. Sanij, 2011, Cancer research.

ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine.

T. Heffernan, A. Conney, A. Blasina, 2009, The Journal of investigative dermatology.

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

J. Barata, M. G. Silva, K. Anderes, 2010, Blood.

Targeting CK 2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

P. Lucio, J. Barata, M. G. Silva, 2010 .

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

R. Kurzrock, A. Naing, L. Camacho, 2014, Cancer.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2010, Cancer research.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Carleen Cullinane, Ricky W Johnstone, S. Lowe, 2012, Cancer cell.

7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2011, Bioorganic & medicinal chemistry letters.

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010, Clinical Cancer Research.

Fully Human Monoclonal Antibody against R adherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010 .

PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

J. Christensen, K. Zasadny, Guizhen Sun, 2009, Clinical Cancer Research.

Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream® for Detecting (or Monitoring) the Expression of Folate Receptor Alpha

K. Anderes, D. Davis, D. O'Shannessy, 2016, Biomarker insights.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

A. Kuki, Michael D. Johnson, D. Murphy, 2002, Journal of medicinal chemistry.

Human glucagon receptor antagonists based on alkylidene hydrazides.

A. Kuki, D. Murphy, A. Polinsky, 2002, Bioorganic & medicinal chemistry letters.

Identification of alkylidene hydrazides as glucagon receptor antagonists.

A. Kuki, D. Murphy, A. Polinsky, 2001, Journal of medicinal chemistry.

341 POSTER CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity

J. Bliesath, Caroline B. Ho, K. Anderes, 2008 .

Therapeutics , Targets , and Chemical Biology CX-4945 , an Orally Bioavailable Selective Inhibitor of Protein Kinase CK 2 , Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Brien, Adam Siddiqui-Jain, J. Bliesath, 2010 .

Biological Characterization of a Novel, Orally Active Small Molecule Gonadotropin-Releasing Hormone (GnRH) Antagonist Using Castrated and Intact Rats

Mark B. Anderson, G. Paderes, D. Luthin, 2003, Journal of Pharmacology and Experimental Therapeutics.

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

P. O'Connor, A. Blasina, J. Register, 2008, Molecular Cancer Therapeutics.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Preclinical Development CK 2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Ef fi cacy : Mechanistic Rationale for Drug Combination Therapy

D. V. Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012 .

Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream.

A. Tsao, F. Fossella, V. Papadimitrakopoulou, 2013 .

Structure-Based Design of (5-Arylamino-2H-pyrazol-3-yl)-biphenyl-2‘,4‘-diols as Novel and Potent Human CHK1 Inhibitors

Enhong Chen, Ping Chen, Karen Lundgren, 2007 .

Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.

Mark B. Anderson, G. Paderes, D. Luthin, 2002, Bioorganic & medicinal chemistry letters.

Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties.

Adam Siddiqui-Jain, Nicole Streiner, Caroline B. Ho, 2011, Bioorganic & medicinal chemistry letters.

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Amy Lin, D. V. Von Hoff, Adam Siddiqui-Jain, 2009, Cancer research.

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, Cancer letters.

Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.

Roberto Battistutta, L. Pinna, R. Battistutta, 2011, Biochemistry.

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Biochemical and biophysical research communications.

Effect of Testosterone Suppression on the Pharmacokinetics of a Potent GnRH Receptor Antagonist

Mark B. Anderson, D. Luthin, K. Anderes, 2002, Pharmaceutical Research.

Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.

C. Bieberich, Xiang Li, K. Anderes, 2012, Journal of proteome research.

Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models

K. Anderes, C. Painter, M. Arango, 2009, Clinical Cancer Research.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

N. Socci, M. Berger, S. Lowe, 2022, Cancer discovery.

Abstract 1449: ApoStream™, a new dielectrophoretic device for antibody-independent isolation and recovery of circulating tumor cells from blood of patients with metastatic pancreatic adenocarcinoma.

Vladislava O. Melnikova, James L. Abbruzzese, R. Wolff, 2013 .

Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Mark B. Anderson, G. Paderes, D. Luthin, 2006, Journal of medicinal chemistry.

Imaging with FLT-PET demonstrates that PF-477736, an inhibitor of CHK1 kinase, overcomes a cell cycle checkpoint induced by gemcitabine in PC-3 xenografts.

G. McArthur, A. Blasina, R. Hicks, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Adam Siddiqui-Jain, J. Bliesath, Nicole Streiner, 2010 .

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

Abstract A079: Subpopulation heterogeneity demonstrated in circulating tumor cells isolated from breast cancer patients using ApoStream, an antibody-independent cancer cell recovery device

K. Anderes, Vishal Gupta, V. Melnikova, 2013 .

414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial

D. Northfelt, D. V. Hoff, K. Anderes, 2010 .

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

S. Lowe, C. Schmitt, R. Pearson, 2012, Cancer cell.

PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

J. Christensen, K. Zasadny, Guizhen Sun, 2009, Clinical Cancer Research.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

R. Kurzrock, A. Naing, L. Camacho, 2014, Cancer.

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010, Clinical Cancer Research.

373 POSTER Characterization of a novel and selective inhibitor of checkpoint kinase 1: breaching the tumor's last checkpoint defense against chemotherapeutic agents

C. Fleur, P. O'Connor, A. Blasina, 2006 .

526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3

A. Tolcher, F. Meric-Bernstam, D. Voliotis, 2021, Annals of Oncology.